Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
The Global Mantle Cell Lymphoma Market offers significant growth potential driven by an aging population increasing cancer ...
The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
The memorial celebration for Bret Hanna-Shuford will be live streamed. Bret Hanna-Shuford passed away recently at the age of ...
Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune ...
Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...
Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
Corvus Pharmaceuticals, Inc. jumps 165% on Phase 1 soquelitinib atopic dermatitis data; learn key efficacy, funding, and ...
GlobalData on MSN
Genmab reports top line results in Phase III DLBCL trial
Genmab plans to present full results at an upcoming medical meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results